Happy Holidays and New year from the EMDB! Please be advised that the EMDB team will be operating at reduced capacity between December 15th - January 12th. With this in mind we would ask that you be prepared for longer reply times through both our helpdesk system and the OneDep deposition system. well done on a productive 2025, wishing you all the best and we will see you in 2026!

EMD-48525

Single-particle
3.3 Å
EMD-48525
3D View Gallery
Deposition: 03/01/2025
Map released: 12/02/2025
Last modified: 12/02/2025
Overview 3D View Sample Experiment Validation Additional data Links
Overview 3D View Sample Experiment Validation Additional data Links

EMD-48525
Download
3D volume (map.gz) Experimental metadata (xml) Experimental Metadata (cif.gz)
Map-only Validation report (pdf.gz) Map-only Validation report (cif.gz) Map-only Validation report (xml.gz)
Map and PDB model 9mqi summary report (pdf.gz) Map and 9mqi FULL report (pdf.gz)
EMICSS annotations (xml)

Inactive Mu-Opioid Receptor with Nb6M, NabFab, and isoquinuclidine compound#020_E1

EMD-48525

Single-particle
3.3 Å
EMD-48525
3D View Gallery
Deposition: 03/01/2025
Map released: 12/02/2025
Last modified: 12/02/2025
Overview 3D View Sample Experiment Validation Additional data Links
Sample Organism: synthetic construct, Homo sapiens
Sample: Human Mu-Opioid Receptor
Fitted models: 9mqi

Deposition Authors: Kim JY , Vigneron SF , Billesbolle C, Manglik A , Shoichet BK
Docking 14 million virtual isoquinuclidines against the mu and kappa opioid receptors reveals dual antagonists-inverse agonists with reduced withdrawal effects.
Vigneron SF , Ohno S , Braz J, Kim JY , Kweon OS , Webb C , Billesbolle C, Bhardwaj K , Irwin J, Manglik A , Basbaum AI , Ellman JA , Shoichet BK
(2025) bioRxiv
PUBMED: 39868130
DOI: doi:10.1101/2025.01.09.632033
ISSN: 2692-8205